In multiple clinical trials, APR246 combined with azacitidine has demonstrated enhanced anti-tumor activity, leading to higher response rates in TP53-mutated AML and MDS compared to azacitidine alone (79–81). This evidence concerns the gene TP53 and myelodysplastic syndrome.